New targeted therapy improved survival for patients with KRAS-mutated lung cancer

Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS-targeted therapy divarasib, according to researchers from The University of Texas MD Anderson Cancer Center.

Read it at Medical Xpress ↗

← Front page